Overcoming Medical Challenges in HNSCC Using Novel Immune Modulatory Treatment Options

Directly engage with experts during this unique symposium focused on practical guidance in integrating immunotherapy agents into therapeutic strategies to improve outcomes for patients with HNSCC. Benefit from expert insights into multiple settings including newly diagnosed locoregionally advanced and recurrent metastatic disease.

The 2018 Multidisciplinary Head and Neck Cancers Symposium Steering Committee has reviewed and approved this symposium as appropriate for presentation as an Industry Satellite Symposium (ISS). The ISS constitutes the content and views of the sponsor and is not part of the official 2018 Multidisciplinary Head and Neck Cancers Symposium program.

Not able to attend the symposium? Log in to a live simulcast to participate remotely.

Join now


7:00 PM Overview of Immunotherapy for Cancer
Maura L. Gillison, MD, PhD

7:30 PM Clinical Development of Immune Checkpoint Inhibitors in Head and Neck Cancer
Everett Vokes, MD

8:00 PM Management of Immune-Related Adverse Events and Future Directions
Barbara Burtness, MD

8:30 PM Discussion of Select Abstracts From the Conference
Faculty Panel


Date / Time
Event Details


Program Director
Maura Gillison, MD, PhD

Division of Cancer Medicine
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Barbara Ann Burtness, MD

Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Everett Vokes, MD

John E. Ultmann Professor
Chairman, Department of Medicine
University of Chicago Medical and Biologic Sciences
Chicago, Illinois

Program Overview
This symposium focuses on integrating immunotherapy agents into therapeutic strategies to improve outcomes for patients with HNSCC. The program will include didactic presentations and interactive case discussion with expert faculty.

Goal Statement
The goal of this activity is to improve participants’ competence in incorporating immunotherapies in the treatment of patients with head and neck squamous cell carcinoma.

Target Audience
This program is intended for medical oncologists, radiation oncologists, surgical oncologists, and head and neck surgeons who care for patients with head and neck squamous cell carcinoma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Explain the role of the immune system and immune escape in HNSCC, along with the mechanisms of action of different immune modulatory agents
  • Plan therapeutic strategies for patients with recurrent metastatic HNSCC that has progressed on or after platinum-containing chemotherapy
  • Discuss the latest science and clinical trial results of immunotherapy agents or combinations being investigated as first-line treatment of locoregionally advanced or metastatic HNSCC
  • Identify appropriate candidates for clinical trials of IDO inhibitors and other emerging immune modulatory agents alone or in combination for HNSCC
  • Identify and manage immune-related toxicities associated with immune checkpoint inhibitors in patients with HNSCC


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.